Keith Meister Sells 457,858 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Illumina Stock Performance

ILMN opened at $187.96 on Friday. The firm’s fifty day simple moving average is $181.13 and its two-hundred day simple moving average is $149.05. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $207.00. The company has a market cap of $28.38 billion, a price-to-earnings ratio of 35.07, a PEG ratio of 2.73 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ILMN. HighPoint Advisor Group LLC increased its stake in Illumina by 3.7% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after purchasing an additional 80 shares in the last quarter. Elevation Wealth Partners LLC boosted its position in shares of Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after purchasing an additional 84 shares in the last quarter. Meeder Advisory Services Inc. boosted its position in shares of Illumina by 3.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after purchasing an additional 85 shares in the last quarter. Toronto Dominion Bank grew its stake in shares of Illumina by 0.3% in the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after buying an additional 92 shares during the period. Finally, Panagora Asset Management Inc. increased its position in Illumina by 3.9% in the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after buying an additional 96 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ILMN has been the subject of several recent research reports. Barclays raised their price objective on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research note on Friday, July 31st. Royal Bank Of Canada upped their target price on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price target on shares of Illumina in a research report on Friday, July 31st. Piper Sandler restated an “overweight” rating and issued a $225.00 price target (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. Finally, JPMorgan Chase & Co. upped their price objective on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $188.40.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Zacks upgraded Illumina to Rank #1, or “Strong Buy,” citing improving earnings prospects and strong momentum characteristics. The upgrade could attract near-term buying interest. What Makes Illumina a New Strong Buy Stock
• Positive Sentiment: Illumina’s latest quarterly results provide a supportive backdrop: earnings per share exceeded estimates, revenue topped forecasts, and sales increased 9.4% year over year. The company continues to guide to fiscal 2026 EPS of $5.30 to $5.40. Recent bullish analysts have raised price targets as high as $230. Illumina Earnings and Analyst Information
• Neutral Sentiment: Analyst opinion remains divided. Although several firms maintain Buy or Outperform ratings, the consensus rating is “Hold,” with an average price target of $188.40—close to recent trading levels—suggesting limited consensus upside.
• Negative Sentiment: Director Keith A. Meister sold 741,127 shares across August 4 and 5 for approximately $148.2 million, reducing his position by about 28%. He retains more than 2 million shares, but the size of the transactions may pressure sentiment and raise concerns about insider confidence. Illumina Insider Trading Filing
• Negative Sentiment: Bank of America Securities reiterated its “Sell” rating and $140 price target, arguing that a one-time consumables benefit may be masking weak underlying demand. The target is well below recent levels, highlighting valuation and sustainability concerns. Bank of America Maintains Sell Rating

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.